ATTR Cardiac Amyloidosis
About Course
Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis in Kenya:
This educational activity is supported by an independent medical education grant from the Mayo Clinic and Pfizer, Inc.
This CPD-accredited online course is designed to enhance the knowledge, diagnostic accuracy, and clinical response of healthcare professionals in Kenya regarding transthyretin (TTR) cardiac amyloidosis, a serious and underrecognized cause of heart failure. Through an evidence-based and locally contextualized curriculum, the course empowers clinicians to identify red flags, select and interpret appropriate diagnostic tools, and apply best-practice management strategies, including genetic counseling and advanced imaging.
Participants will engage with dynamic learning modules, animated explainer videos, expert interviews, and real-world clinical cases to sharpen diagnostic reasoning and multidisciplinary collaboration. The course also introduces emerging therapies and surveillance strategies tailored to both wild-type and hereditary forms of ATTR-CM.
Whether you’re a cardiologist, internal medicine specialist, radiologist, lab expert, or front-line provider, this course equips you with the tools to ensure earlier diagnosis, improve patient outcomes, and bridge critical gaps in care across Kenya.
Anders Barasa, MD, PhD
John Heshmat, PharmD, MSc
Course Content
ATTR-CM Comprehensive Knowledge Assessment
ATTR-CM Comprehensive Knowledge Assessment (Note: This quiz is for knowledge assessment only; no points will be awarded)